Lipocine Inc. (LPCN): R&D Expense
$8.58M
Year ended 2025-12-31
$10.19M
Trailing 12 months to 2026-06-30
+0.1%
3-year compound annual growth
-2.5%
5-year compound annual growth
-3.8%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $8.58M | +16.8% | 2026-03-10, From 2025-01-01 |
| 2024-12-31 | $7.35M | -27.7% | 2026-03-10, From 2024-01-01 |
| 2023-12-31 | $10.18M | +18.9% | 2025-03-13, From 2023-01-01 |
| 2022-12-31 | $8.56M | +11.6% | 2024-03-07, From 2022-01-01 |
| 2021-12-31 | $7.67M | -21.4% | 2023-03-10, From 2021-01-01 |
| 2020-12-31 | $9.75M | +30.5% | 2022-03-09, From 2020-01-01 |
| 2019-12-31 | $7.47M | +15.5% | 2021-03-11, From 2019-01-01 |
| 2018-12-31 | $6.46M | -41.3% | 2020-03-13, From 2018-01-01 |
| 2017-12-31 | $11.00M | +36.3% | 2019-03-06, From 2017-01-01 |
| 2016-12-31 | $8.08M | -35.8% | 2019-03-06, From 2016-01-01 |
| 2015-12-31 | $12.58M | -18.7% | 2018-03-12, From 2015-01-01 |
| 2014-12-31 | $15.48M | +202.2% | 2017-03-06, From 2014-01-01 |
| 2013-12-31 | $5.12M | +124.6% | 2015-03-11, From 2013-01-01 |
| 2012-12-31 | $2.28M | n/a | 2014-03-31, From 2012-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Lipocine Inc. (LPCN) | 2025-12-31 | $8.58M | +16.8% |
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | $145.64M | +75.2% |
| Korsana Biosciences, Inc. (KRSA) | 2025-12-31 | $959.0K | +235.3% |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | $20.20M | -24.3% |
| GeoVax Labs, Inc. (GOVX) | 2025-12-31 | $18.12M | -23.6% |
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | $3.78M | -39.1% |
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | $1.04M | -84.4% |
| Cartesian Therapeutics, Inc. (RNAC) | 2025-12-31 | $58.03M | +28.7% |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | $28.79M | -17.5% |
Compare LPCN, DNTH, KRSA, RANI side by side · Screen every company in Pharmaceutical Preparations ↗